Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameAnti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine)
Drug Alias NameGlypican-3- chimeric-antigen-receptor-T-cell-therapy - Hunan Yongren Medical InnovationAnti-GPC3 CAR-T cellsAnti-GPC3 chimeric antigen receptor T cell therapy - Guangdong Zhaotai InVivo Biomedicine/Hunan Yongren Medical InnovationGPC3-CAR-T cell therapy - Hunan Yongren Medical InnovationGPC3-T2-CAR-T cell therapy +[6] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitorsInterleukin-7 receptors agonists +[7] 
TargetsGlypican-3Interleukin-7 receptorsC-C chemokine receptor type 7 +[6] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHunan Zhaotai Yongren Biotech Co LtdGuangdong Zhaotai Invivo Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Zhaotai Invivo Biomedicine Co LtdHunan Zhaotai Yongren Medical Innovation Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A